Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$114.02

0.95 (0.84%)

, ALIOF

Actelion

$153.55

-3.24 (-2.07%)

13:11
11/25/16
11/25
13:11
11/25/16
13:11

On The Fly: Top stock stories for Friday

Stocks on Wall Street hit fresh all-time highs over the first three sessions this week and continued their uptrend in today's holiday-shortened session. The ongoing "Trump rally," along with expectations for a strong holiday season, buoyed stocks, with retailers among the notable gainers on this Black Friday. ECONOMIC EVENTS: In the U.S., the advance trade report showed a jump to $62.0B in the deficit in October, larger than the $59.0B deficit expected for last month. Markit's services PMI for November came in at 54.7 in the flash reading, which was a tick below the 54.8 reading that was forecast by analysts. COMPANY NEWS: Black Friday sales are underway, with several retailers rising in today's trading amid the mass shopping event. Target (TGT) rose about 0.15% after it reported a "strong start" to the holiday shopping season, saying that millions of guests visited the company's stores across the country and Target.com for Black Friday. Wal-Mart (WMT) also rose roughly 0.5%, with the retail giant noting that 70% of Black Friday traffic to Walmart.com was driven by mobile... In possible mergers and acquisitions news, Actelion (ALIOF) and Johnson & Johnson (JNJ) each confirmed in separate press releases that they are engaged in preliminary talks over a potential transaction. Johnson & Johnson rose about 1% to close at $114.13 after the news, while shares of Actelion trading in New York finished the day nearly 20% higher. MAJOR MOVERS: Among the notable gainers was Insteel (IIIN), which rose 16% after it was named to replace Littlefuse (LFUS) in the S&P 600 as of the November 28 close. Also higher was Ctrip.com (CTRP), which advanced almost 10% after reporting better than expected third quarter revenue and earnings and announcing an agreement to acquire Skyscanner after the closing bell on Wednesday. Among the noteworthy losers was Airgain (AIRG), which fell 13.5% after it announced the release of lock up restrictions with Northland in connection with its initial public offering. INDEXES: The Dow rose 68.96, or 0.36%, to 19,152.14, the Nasdaq gained 18.24, or 0.34%, to 5,398.92, and the S&P 500 advanced 8.63, or 0.39%, to 2,213.35.

JNJ

Johnson & Johnson

$114.02

0.95 (0.84%)

ALIOF

Actelion

$153.55

-3.24 (-2.07%)

TGT

Target

$78.55

0.065 (0.08%)

WMT

Wal-Mart

$71.11

0.28 (0.40%)

IIIN

Insteel

$36.58

0.76 (2.12%)

LFUS

Littelfuse

$149.72

2.81 (1.91%)

CTRP

Ctrip.com

$40.99

-0.88 (-2.10%)

AIRG

Airgain

$26.95

0.2 (0.75%)

  • 29

    Nov

  • 29

    Nov

  • 01

    Dec

  • 09

    Dec

JNJ Johnson & Johnson
$114.02

0.95 (0.84%)

10/18/16
UBSW
10/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson robust pipeline underappreciated, says UBS
UBS analyst Matt Miksic said the Johnson & Johnson pipeline remains robust and is underappreciated. The analyst said the recent launch of biosimilars removes uncertainty and should be positive for the stock. He also expects the additional deployment of the company's capital - to expand its pipeline through in-licensing, partnerships or mid-sized acquisitions - to be incremental to his Buy thesis. Miksic has a $137 price target on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.
ALIOF Actelion
$153.55

-3.24 (-2.07%)

TGT Target
$78.55

0.065 (0.08%)

09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Target initiated with a Neutral at Guggenheim
09/16/16
FBCO
09/16/16
INITIATION
Target $65
FBCO
Neutral
Target coverage assumed with a Neutral at Credit Suisse
Credit Suisse analyst Edward Kelly assumed coverage on Target with a $65 price target, down from $72, citing an uncertain outlook, structural headwinds, and under investment.
09/16/16
09/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GoPro (GPRO) initiated with a Buy at BofA/Merrill. 2. JetBlue (JBLU) initiated with an Outperform at Imperial Capital. 3. PepsiCo (PEP), Dr Pepper Snapple (DPS), and Monster Beverage (MNST) were initiated with an Outperform at Credit Suisse, while the firm initiated Boston Beer (SAM) with an Underperform. Credit Suisse also initiated Coca-Cola (KO) and Constellation Brands (STZ) with a Neutral. 4. lululemon (LULU) initiated with a Positive at Susquehanna. 5. Target (TGT) coverage assumed with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
BOFA
09/23/16
NO CHANGE
Target $55
BOFA
Buy
BofA thinks Verizon deal stays on track despite Yahoo data breach
Bank of America Merrill Lynch analyst Justin Post said that Yahoo's (YHOO) disclosure of the massive data breach impacting over 500M of its users is clearly a negative for the company that could result in email account closures, but he does not anticipate a major impact on Yahoo's business related to this breach, citing as evidence the fact that he is not aware of any significant business impairment or financial liability related to security breaches at LinkedIn (LNKD) in 2012 and at eBay (EBAY) in 2014. Post adds that the Target (TGT) data breach, which did include credit card info, is not directly comparable to Yahoo's breach. For Verizon (VZ) to back out of its acquisition agreement, Post thinks the company would need to assume Yahoo acted in bad faith during negotiations and that the Yahoo asset is impaired or comes with significant liability, neither of which he sees as being the case. The analyst keeps a Buy rating on Yahoo and bumped his target on the shares to $55 from $53, citing an increased price target on Alibaba (BABA) that a peer at the firm recently set.
WMT Wal-Mart
$71.11

0.28 (0.40%)

11/23/16
UBSW
11/23/16
NO CHANGE
Target $100
UBSW
Buy
Dollar Tree price target raised to $100 from $90 at UBS
UBS analyst Michael Lasser raised his price target on Dollar Tree (DLTR) to $100 from $90 following Q3 results. The analyst said the company's results eased a number of fears and demonstrated it could hold its own against competitors such as Wal-Mart (WMT). Dollar Tree exhibited comp growth, and its merger with Family dollar is providing synergies within its guidance, said Lasser, who reiterated his Buy rating on the shares.
11/11/16
BARD
11/11/16
NO CHANGE
Target $80
BARD
Outperform
Wal-Mart 2017 earnings somewhat de-risked, says Baird
Baird analyst Peter Benedict expects Wal-Mart's Q3 results to be generally in-line as investments in associates, processes, and prices are working together to drive improved customer satisfaction and sales. The company's 2017 estimates appear to be de-risked as management reset margin and earnings expectations at last month's investor meeting, said Benedict, who reiterated his Outperform rating and $80 price target on Wal-Mart shares.
11/17/16
BARD
11/17/16
NO CHANGE
Target $80
BARD
Outperform
Wal-Mart strategy remains on track, says Baird
Baird analyst Peter Benedict notes that this was a 'noisy' quarter for Wal-Mart, but underlying EPS effectively in line with expectations. While acknowledging that U.S. traffic gains slowed against a tougher compare and Q4 EPS guidance was viewed as a disappointment, the analyst believes Wal-Mart's strategy remains on track and 2017 EPS estimates appear largely de-risked. He reiterates an Outperform rating and $80 price target on the shares, given the company's defensive appeal within a still choppy consumer/retail backdrop.
10/27/16
JPMS
10/27/16
DOWNGRADE
Target $28
JPMS
Neutral
JPMorgan downgrades Vitamin Shoppe on 2017 earnings risk
JPMorgan analyst Christopher Horvers earlier today downgraded Vitamin Shoppe (VSI) to Neutral from Overweight and lowered his price target for the shares to $28 from $33. The analyst sees downside risk to 2017 earnings as the competitive environment worsens. GNC Holdings (GNC) under new management is testing major pricing and loyalty card changes while Vitamin Shoppe's comparable prices are higher versus Amazon (AMZN), Horvers tells investors in a research note. He sees Vitamin Shoppe "squeezed between" its three larger competitors, GNC, Wal-Mart (WMT) and Amazon. The stock is trading down $2.05 to $25.30 following GNC's Q3 results. GNC is trading down 20% to $16.04.
IIIN Insteel
$36.58

0.76 (2.12%)

11/22/16
SIDC
11/22/16
UPGRADE
Target $44
SIDC
Buy
Insteel upgraded to Buy from Neutral at Sidoti
Sidoti upgraded Insteel to Buy and raised its price target to $44 from $32 siting increased wire rod prices.
04/01/16
SIDC
04/01/16
DOWNGRADE
SIDC
Neutral
Insteel downgraded to Neutral from Buy at Sidoti
Sidoti downgraded Insteel to Neutral citing a PC strand capacity increase from a competitor and maintained its $32 price target on shares.
LFUS Littelfuse
$149.72

2.81 (1.91%)

11/21/16
SIDC
11/21/16
DOWNGRADE
Target $157
SIDC
Neutral
Littelfuse downgraded to Neutral from Buy at Sidoti
Sidoti downgraded Littelfuse to Neutral citing the recent rise in shares and maintained its $157 price target.
10/28/16
OPCO
10/28/16
NO CHANGE
Target $155
OPCO
Outperform
Littelfuse price target raised to $155 from $145 at Oppenheimer
Oppenheimer analyst Christopher Glynn raised his price target for Littelfuse to $155 from $145 after the company raised its Q3 guidance. The analyst reiterates an Outperform rating on the shares.
09/13/16
OPCO
09/13/16
NO CHANGE
Target $145
OPCO
Outperform
Littelfuse price target raised to $145 from $138 at Oppenheimer
Oppenheimer analyst Christopher Glynn raised his price target for Littelfuse to $145 from $138, citing liquidity, acquisition track record, and underlying earnings power runway on portfolio integration. The analyst continues to view shares of Littelfuse as his top pick for strategy deployment and compounding runway over the next several years. He reiterates an Outperform rating on the shares.
09/08/16
BARD
09/08/16
NO CHANGE
Target $132
BARD
Outperform
Littelfuse investors should be aggressive on pullbacks, says Baird
Baird analyst Timothy Wojs met with Littlefuse management and came away more confident that shares should be bought aggressively on any pullbacks. The analyst continues to like the long-term risk/reward given the company's relatively solid organic growth and execution as well as recent M&A activity, which had provided some upside bias to numbers over time. Wojs reiterated his Outperform rating and $132 price target on Littlefuse shares.
CTRP Ctrip.com
$40.99

-0.88 (-2.10%)

11/25/16
HSBC
11/25/16
UPGRADE
HSBC
Buy
Ctrip.com upgraded to Buy from Hold at HSBC (yesterday)
11/25/16
JPMS
11/25/16
NO CHANGE
Target $55
JPMS
Overweight
JPMorgan turning more positive on Ctrip.com outlook
JPMorgan analyst Alex Yao says he's turning more positive on Ctrip.com's profit outlook following the company's Q3 results. The company's operating efficiency is improving while Qunar is turning profitable, Yao tells investors in a research note. The analyst views the Skyscanner acquisition as "solid progress" toward expanding into the addressable market for the outbound travel business. He maintains an Overweight rating on Ctrip.com with a $55 price target. The Chinese travel service provider is up $3.51 to $44.50 in pre-market trading.
11/25/16
SBSH
11/25/16
NO CHANGE
Target $55
SBSH
Buy
Ctrip.com strengthening position in global travel market, says Citi
Citi analyst Alicia Yap views Ctrip.com's Q3 results as "solid" and keeps a Buy rating on the shares with a slightly reduced price target of $55. The company, after dominating the China online travel booking landscape, is "stepping up its positioning" in the global online travel market via recent acquisitions, Yap tells investors in a research note. Ctrip has enhanced its global product offerings for both air and hotels, the analyst contends.
11/25/16
BMUR
11/25/16
NO CHANGE
Target $54
BMUR
Buy
Ctrip.com represents unique investment opportunity, says Brean Capital
Brean Capital analyst Fawne Jiang said Ctrip.com represents a unique opportunity for investors. The analyst sees a number of levers in the business model that appear to be ready to play out in the coming years, including consolidation in the domestic travel market, strategic investments in overseas resources, its acquisition of Skyscanner, and a strengthening of its market leading position in China. Jiang reiterated her Buy rating and raised her price target to $54 from $52 on Ctrip shares.
AIRG Airgain
$26.95

0.2 (0.75%)

10/31/16
WDLK
10/31/16
UPGRADE
Target $16
WDLK
Buy
Airgain upgraded to Buy on recent pullback at Wunderlich
Wunderlich analyst Matthew Robison upgraded Airgain to Buy from Hold saying the recent pullback in shares has created an attractive entry point. The company's business continues to progress, Robison tells investors in a research note. He raised his price target for the shares to $16 from $14.
10/31/16
WDLK
10/31/16
UPGRADE
WDLK
Buy
Airgain upgraded to Buy from Hold at Wunderlich
Wunderlich analyst Matthew Robison upgraded Airgain to Buy.
09/21/16
WDLK
09/21/16
DOWNGRADE
Target $14
WDLK
Hold
Airgain downgraded to Hold from Buy at Wunderlich
Wunderlich analyst Matthew Robison downgraded Airgain to Hold with a $14 price target following the company's Q2 results.
09/06/16
NORL
09/06/16
INITIATION
Target $15
NORL
Outperform
Airgain initiated with an Outperform at Northland
Northland analyst Tom Sepenzis initiated Airgain with an Outperform rating and $15 price target.

TODAY'S FREE FLY STORIES

SGMO

Sangamo

19:39
12/05/16
12/05
19:39
12/05/16
19:39
Hot Stocks
Sangamo reports preclinical, manufacturing data on SB-525, says IND on track »

Sangamo BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

, BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

19:38
12/05/16
12/05
19:38
12/05/16
19:38
Hot Stocks
Seattle Genetics, Bristol-Myers: Data supports ADCETRIS, Opdivo combo »

Seattle Genetics (SGEN)…

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

LGIH

LGI Homes

$32.34

0.45 (1.41%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
LGI Homes reports November home closings up 28.9% y/y »

LGI Homes announced 321…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$116.56

-1.07 (-0.91%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
Celgene reports analysis of three CC-486 studies »

Celgene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BLUE

bluebird bio

$72.15

2.4 (3.44%)

19:35
12/05/16
12/05
19:35
12/05/16
19:35
Hot Stocks
bluebird bio provides updates on HSC gene therapy programs »

bluebird bio provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$49.88

-7.09 (-12.45%)

19:33
12/05/16
12/05
19:33
12/05/16
19:33
Hot Stocks
Agios 'encouraged' by durable clinical activity of AG-120 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$60.25

-0.88 (-1.44%)

19:31
12/05/16
12/05
19:31
12/05/16
19:31
Hot Stocks
Merck: KEYNOTE-087 trial data shows oORR of 69%, CRR of 22.4% »

Merck announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Mar

TWX

Time Warner

$93.34

-0.46 (-0.49%)

, T

AT&T

$38.63

0.02 (0.05%)

19:29
12/05/16
12/05
19:29
12/05/16
19:29
Periodicals
Time Warner 'struggling to expand' HBO Now, NY Post says »

Time Warner (TWX) is…

TWX

Time Warner

$93.34

-0.46 (-0.49%)

T

AT&T

$38.63

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

BP

BP

, REPYY

Repsol

$13.88

0.25 (1.83%)

19:18
12/05/16
12/05
19:18
12/05/16
19:18
Periodicals
BP acquires Repsol stake in Indonesia LNG plant, Reuters says »

BP (BP) has purchased…

BP

BP

REPYY

Repsol

$13.88

0.25 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSUF

Fosun

19:12
12/05/16
12/05
19:12
12/05/16
19:12
Hot Stocks
Liberty Mutual to acquire Fosun subsidiary Ironshore for roughly $3B »

Liberty Mutual Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$49.75

-0.06 (-0.12%)

, YHOO

Yahoo

$40.20

0.13 (0.32%)

18:54
12/05/16
12/05
18:54
12/05/16
18:54
Periodicals
AOL CEO 'cautiously optimistic' Verizon-Yahoo deal will go through, WSJ says »

AOL CEO Tim Armstrong…

VZ

Verizon

$49.75

-0.06 (-0.12%)

YHOO

Yahoo

$40.20

0.13 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 24

    Jan

TUWOY

Tullow Oil

$2.06

0.109 (5.58%)

18:46
12/05/16
12/05
18:46
12/05/16
18:46
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$22.15

0.75 (3.50%)

18:43
12/05/16
12/05
18:43
12/05/16
18:43
Hot Stocks
Breaking Hot Stocks news story on Guaranty Bancorp »

Castle Creek raises stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$20.48

-0.18 (-0.87%)

18:41
12/05/16
12/05
18:41
12/05/16
18:41
Syndicate
Atkore files to sell 8M shares of common stock for holders »

The offering is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$107.42

-0.8 (-0.74%)

18:38
12/05/16
12/05
18:38
12/05/16
18:38
Hot Stocks
United Technologies CEO: No quid pro quo on taxes in Carrier deal with Trump »

Says Carrier agreement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPDN

Professional Diversity Network

$9.75

-0.01 (-0.10%)

18:37
12/05/16
12/05
18:37
12/05/16
18:37
Hot Stocks
Breaking Hot Stocks news story on Professional Diversity Network »

North Star cuts passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHXM

DHX Media

$5.05

-0.36 (-6.65%)

18:33
12/05/16
12/05
18:33
12/05/16
18:33
Hot Stocks
Breaking Hot Stocks news story on DHX Media »

Luxor Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPHS

Trinity Place

$10.02

0.08 (0.80%)

18:24
12/05/16
12/05
18:24
12/05/16
18:24
Hot Stocks
Trinity Place Holdings, Pacolet Milliken acquire Brooklyn building for $68.8M »

Trinity Place Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$32.46

0.23 (0.71%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Suncor Energy resolves C$1.3B tax dispute with Canada Revenue Agency »

Suncor Energy reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

, CELG

Celgene

$116.56

-1.07 (-0.91%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Acceleron, Celgene report Phase 2 data on luspatercept in beta-thalassemia »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

CELG

Celgene

$116.56

-1.07 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

SNSS

Sunesis

$4.02

0.12 (3.08%)

17:54
12/05/16
12/05
17:54
12/05/16
17:54
Hot Stocks
Sunesis says new VALOR trial data show 'compelling durable survival outcomes' »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$26.02

-0.27 (-1.03%)

, BOBE

Bob Evans

$46.77

1.05 (2.30%)

17:52
12/05/16
12/05
17:52
12/05/16
17:52
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Coupa…

COUP

Coupa Software

$26.02

-0.27 (-1.03%)

BOBE

Bob Evans

$46.77

1.05 (2.30%)

TXMD

TherapeuticsMD

$6.17

0.04 (0.65%)

KMI

Kinder Morgan

$21.46

0.1 (0.47%)

SB

Safe Bulkers

LXRX

Lexicon

$15.64

0.66 (4.41%)

FET

Forum Energy

$23.20

1.15 (5.22%)

RCII

Rent-A-Center

$11.91

0.38 (3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 28

    Feb

  • 06

    Dec

KPTI

Karyopharm

$8.87

-0.41 (-4.42%)

17:47
12/05/16
12/05
17:47
12/05/16
17:47
Hot Stocks
Karyopharm presents updated Phase 1b STOMP data at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BOBE

Bob Evans

$46.77

1.05 (2.30%)

17:47
12/05/16
12/05
17:47
12/05/16
17:47
Hot Stocks
Bob Evans says evaluating potential opportunities for value creation »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

17:46
12/05/16
12/05
17:46
12/05/16
17:46
Hot Stocks
Google posts job listing for 'conservative outreach' manager »

Google has posted a job…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.